Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Milvexian - Bristol-Myers Squibb/Johnson & Johnson Innovative Medicine

Next Previous
Drug Profile

Milvexian - Bristol-Myers Squibb/Johnson & Johnson Innovative Medicine

Alternative Names: BMS 177; BMS-986177; JNJ-3093; JNJ-70033093

Latest Information Update: 27 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Johnson & Johnson Innovative Medicine
  • Class Antiarrhythmics; Antithrombotics; Aza compounds; Cardiovascular therapies; Chlorobenzenes; Fluorine compounds; Macrocyclic compounds; Pyrimidinones; Small molecules; Triazoles; Vascular disorder therapies
  • Mechanism of Action Factor XIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute coronary syndromes; Atrial fibrillation; Stroke
  • Discontinued Venous thromboembolism

Most Recent Events

  • 14 Nov 2025 Bristol-Myers Squibb terminates a phase III LIBREXIA-ACS trial in Acute coronary syndrome in US, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Switzerland, Taiwan, Thailand, Turkey, and United Kingdom because the trial is not likely to meet primary endpoint
  • 14 Sep 2025 Pharmacokinetics and safety data from a phase I pharmacokinetics trial in healthy volunteers presented at the 2025 American College of Clinical Pharmacology Annual Meeting (ACCP-2025)
  • 14 Sep 2025 Pharmacokinetics and safety data from a phase I drug-drug interaction trial (In volunteers) presented at the 2025 American College of Clinical Pharmacology Annual Meeting (ACCP-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top